1. Home
  2. TRDA vs EAF Comparison

TRDA vs EAF Comparison

Compare TRDA & EAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.99

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Logo GrafTech International Ltd.

EAF

GrafTech International Ltd.

HOLD

Current Price

$6.18

Market Cap

429.4M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
EAF
Founded
2016
1886
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
481.6M
429.4M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
TRDA
EAF
Price
$11.99
$6.18
Analyst Decision
Strong Buy
Hold
Analyst Count
2
4
Target Price
$20.00
$11.75
AVG Volume (30 Days)
190.2K
276.0K
Earning Date
05-07-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,421,000.00
$504,134,000.00
Revenue This Year
$39.97
$4.25
Revenue Next Year
$50.80
$12.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$0.55
52 Week High
$13.99
$20.32

Technical Indicators

Market Signals
Indicator
TRDA
EAF
Relative Strength Index (RSI) 49.24 43.09
Support Level $10.78 $5.90
Resistance Level $12.56 $7.47
Average True Range (ATR) 0.78 0.55
MACD -0.10 0.33
Stochastic Oscillator 30.58 45.36

Price Performance

Historical Comparison
TRDA
EAF

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About EAF GrafTech International Ltd.

GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.

Share on Social Networks: